Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen, Bind Partner To Develop Targeted Nanomedicine For Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen will develop a targeted cancer medicine using a novel Accurin from Bind’s nanomedicine platform and one of its proprietary kinase inhibitors; the deal represents the first major partnership applying a nanomedicine technology to a molecularly targeted drug.

You may also be interested in...



Bind Preps For Important Catalysts In 2014

The nanomedicine developer said it expects to have results from two Phase II trials before the end of the year potentially validating its technology platform during its first year-end sales and earnings call since completing an IPO in September.

Stealth Ninja Nanoparticle Increases Uptake Of Imaging Agents And Drugs

Researchers have devised a tiny synthetic peptide that signals macrophages scavenging for foreign invaders in the body to ignore it and move on. The molecule can be attached to imaging agents, drugs, and biologics, increasing their uptake by shielding them from attack by the immune system.

BIND Nanotherapy Shows Early Cancer Efficacy In The Clinic

Strong preclinical data for BIND-014, docetaxel-carrying particles engineered using BIND’s Accurin platform, translated into positive results against tumors not usually vulnerable to the cancer drug, the company reported at a late-breaker poster session of the American Association for Cancer Research annual meeting.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel